The clinical and economic burden of chronic obstructive pulmonary disease in the USA

Anthony J Guarascio, Shauntá M Ray, Christopher K Finch, Timothy H Self, Anthony J Guarascio, Shauntá M Ray, Christopher K Finch, Timothy H Self

Abstract

Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the USA. In 2010, the cost of COPD in the USA was projected to be approximately US$50 billion, which includes $20 billion in indirect costs and $30 billion in direct health care expenditures. These costs can be expected to continue to rise with this progressive disease. Costs increase with increasing severity of disease, and hospital stays account for the majority of these costs. Patients are diagnosed with COPD following a multifactorial assessment that includes spirometry, clinical presentation, symptomatology, and risk factors. Smoking cessation interventions are the most influential factor in COPD management. The primary goal of chronic COPD management is stabilization of chronic disease and prevention of acute exacerbations. Bronchodilators are the mainstay of COPD therapy. Patients with few symptoms and low exacerbation risk should be treated with a short-acting bronchodilator as needed for breathlessness. Progression of symptoms, as well as possible decline in forced expiratory volume in the first second of expiration (FEV1), warrant the use of long-acting bronchodilators. For patients with frequent exacerbations with or without consistent symptoms, inhaled corticosteroids should be considered in addition to a long-acting beta2-agonist (LABA) or long-acting muscarinic antagonist (LAMA) and may even consist of "triple therapy" with all three agents with more severe disease. Phosphodiesterase-4 inhibitors may be an option in patients with frequent exacerbations and symptoms of chronic bronchitis. In addition to a variety of novel ultra-LABAs, LAMAs and combination bronchodilator and inhaled corticosteroid (ICS) therapies, other bronchodilators with a variety of mechanisms are also being considered, to expand therapeutic options for the treatment of COPD. With more than 50 new medications in the pipeline for the treatment of COPD, optimal management will continue to evolve and grow more complex as benefits of therapy are balanced with the limitations and needs of each patient.

Keywords: COPD; chronic obstructive pulmonary disease; clinical burden; economic burden.

Figures

Figure 1
Figure 1
Evaluative questions from the COPD Assessment Test (CAT). COPD Assessment Test and the CAT logo is a trade mark of the GlaxoSmithKline group of companies. © 2009 GlaxoSmithKline group of companies. All rights reserved. Last Updated: February 24, 2012. Abbreviation: COPD, chronic obstructive pulmonary disease.

References

    1. American Lung Association [updated 2011] COPD Fact Sheet Available from: Accessed October 9, 2012
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013Global Strategy for the Diagnosis, Management and Prevention of COPD Available from: Accessed January 29, 2013
    1. Viegi G, Pistelli F, Sherrill DL, Malo S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007;30:993–1013.
    1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977;1:1645–1648.
    1. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67:495–501.
    1. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67:238–243.
    1. Garcia-Aymerich J, Pons IS, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment COPD hospitalisations and subsequent mortality. Thorax. 2011;66:585–590.
    1. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–212.
    1. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:982–988.
    1. Marti S, Munoz X, Rios J, Morell F, Ferrer J. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J. 2006;27:689–696.
    1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504.
    1. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:188–207.
    1. Thornton Snider J, Romley JA, Wong KS, Zhang J, Eber M, Goldman DP. The disability burden of COPD. COPD. 2012;9(5):513–521.
    1. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118:1278–1285.
    1. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7:214–228.
    1. O’Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J. 2006;15:346–353.
    1. Connors AF, Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe choronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:959–967.
    1. Elixhauser A, Au DH, Podulka J.Statistical Brief #121: Readmissions for Chronic Obstructive Pulmonary Disease 2008US Agency for Healthcare Research and Quality; Available from: Accessed December 20, 2012
    1. American Lung Association Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and mortality Available from: Accessed May 2, 2013
    1. Center for Medicare Advocacy Medicare Hospital Readmissions Available from: Accessed May 2, 2013
    1. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare Fee-for-Service program. N Engl J Med. 2009;360:1418–1428.
    1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138.
    1. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–191.
    1. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pumonary disease. Lancet. 2009;374:721–732.
    1. Joish VN, Brady E, Stockdale W, Brixer DI, Dirani R. Evaluating diagnosis and treatment patterns of COPD in primary care. Treat Respir Med. 2006;5:283–293.
    1. Yawn BP, Enright PL, Lemanske RF, et al. Spirometry can be done in family physicians’ offices and alters clinical decisions in management of asthma and COPD. Chest. 2007;132(4):1162–1168.
    1. Zielinski J, Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. Chest. 2001;119:731–736.
    1. Melbye H, Drivenes E, Dalbak LG, Leinan T, Hoegh-Henrichsen S, Ostrem A. Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more. Int J Chron Obstruct Pulmon Dis. 2011;6:597–603.
    1. Price D, Yawn B, Jones RCM. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin Proc. 2010;85:1122–1129.
    1. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99.
    1. Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a Self-Scored COPD Population Screener Questionnaire (COPD-PS) COPD. 2008;5:85–95.
    1. Bestall JC, Paul EA, Garrod R, Gornham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) Dyspnea Scale as a measure of disability in patients with Chronic Obstructive Pulmonary Disease. Thorax. 1999;54:581–586.
    1. Gruffydd-Jones K, Marsden HC, Holmes S, et al. Utility of COPD Assessment Test (CAT) in primary care consultations: a randomised controlled study. Prim Care Respir J. 2013;22:37–43.
    1. Washko GR. The role and potential of imaging in COPD. Med Clin North Am. 2012;96:729–743.
    1. Brenner DJ, Hall EJ. Computed tomography – an increasing source of radiation exposure. N Engl J Med. 2007;357:2277–2284.
    1. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497–1505.
    1. Burchfiel CM, Marcus EB, Curb JD, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med. 1995;151:1778–1785.
    1. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest. 2006;130:334–342.
    1. Jimenez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001;119:1365–1370.
    1. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives A Clinical Practice Guideline for Treating Tobacco Use and Dependence: a US Public Health Service Report. JAMA. 2000;283:3244–3254.
    1. Fiore MC, Hatsukami DK, Baker TB. Effective tobacco dependence treatment. JAMA. 2002;288:1768–1771.
    1. COPD Working Group Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1–64.
    1. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590–615.
    1. Milstone AP. Use of azithromycin in the treatment of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2008;3:515–520.
    1. Albert RK, Connett J, Bailey WC, et al. COPD Research Network Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698.
    1. Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive Pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139–1147.
    1. US Food Drug Administration FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the Risk of Potentially Fatal Heart Rhythms Available from: Accessed March 12, 2013
    1. Wenzel RP, Fowler AA, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med. 2012;367:340–347.
    1. Combivent inhalation aerosol study group In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105:1411–1419.
    1. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest. 1999;115:635–641.
    1. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005:CD002876.
    1. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006:CD001104.
    1. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47–55.
    1. Brusasco V, Hodder R, Miravitlles M, et al; Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399–404.
    1. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511–1520.
    1. Vogelmeier C, Hederer B, Glaab T, et al. POET-COPD Investigators Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–1103.
    1. Chon J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012:CD009157.
    1. Van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214–222.
    1. Van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respirol. 2010;104:995–1004.
    1. Tashkin DP, Donohue JF, Mahler D, et al. Effects of arformoterol twice daily, tiotropium once daily and their combination in patients with COPD. Respir Med. 2009;103:516–524.
    1. Rossi A, Gottfried SB, Higgs BD, Zocchi L, Grassino A, Milic-Emili J. Respiratory mechanics in mechanically ventilated patient with respiratory failure. J Appl Physiol. 1085;131:747–751.
    1. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2003;361:449–456.
    1. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–919.
    1. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81.
    1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;256:775–789.
    1. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:144–149.
    1. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26.
    1. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317–326.
    1. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554.
    1. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–555.
    1. Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592–598.
    1. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741–750.
    1. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lancet. 2009;374:695–703.
    1. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet. 2009;374:685–694.
    1. Mak G, Hanania N. New bronchodilators. Curr Opin Pharmacol. 2012;12:238–245.
    1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379:1341–1351.
    1. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest. 2007;131:4S–42S.
    1. Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. 1995;109:106–116.
    1. Sachithanandan A, Badmanaban B. Contemporary surgical management of advanced end stage emphysema: an evidence based review. Med J Malaysia. 2012;67(3):253–258.
    1. COPD Assessment Test (CAT) GlaxoSmithKline, Inc 2009[updated October 25, 2012]. Available from: Accessed January 21, 2013

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi